Stockwinners Market Radar for November 22, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:36 EST CACI awarded $112.53M Army contract modification - CACI was awarded a $112.53M modification to a contract for build and test of the Integrated Personnel and Pay System-Army. Work will be performed in Chantilly, Virginia, with an estimated completion date of December 31, 2021. FY10 research, development, test and evaluation funds in the amount of $5M were obligated at the time of the award. U.S. Army Contracting Command, New Jersey, is the contracting activity.

17:24 EST Oyster Point Pharma discloses 'positive' Phase 1 results for OC-01 nasal spray - Oyster Point Pharma announced the positive top-line results from its Phase 1 "ZEN" study in healthy volunteers. The ZEN Study was an open-label, single-center, randomized, 2-way crossover study to evaluate the relative bioavailability of varenicline administered as a preservative-free nasal spray as compared to varenicline administered orally as a single oral dose of Chantix. The ZEN study was designed to assess the relative bioavailability of varenicline administered intranasally at its highest intended clinical strength compared to varenicline administered as a single oral dose at its commercially available maintenance oral tablet strength of 1 mg. The treatment cohort consisted of 22 healthy volunteers who were administered study medication under fasted conditions. Top-line results indicate that the relative bioavailability was 13 times lower for a single dose of the highest strength of OC-01 nasal spray as compared to a single dose of the highest strength Chantix tablet . Maximal concentration was 14 times lower for a single dose of the highest strength of OC-01 nasal spray as compared to a single dose of the highest strength Chantix tablet. The study demonstrated that OC-01 nasal spray was safe and well-tolerated at the doses tested.

17:18 EST Intel board member Goetz buys $5.04M in stock - Intel board member James Goetz purchased 86.5K shares of Intel stock on November 20th, according to a regulatory filing. The transaction has a value of $5.04M.

17:01 EST SAExploration receives Nasdaq non-compliance letter - SAExploration Holdings announced that on November 19, 2019, it received a notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC stating that because the company had not timely filed its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2019 and because the company remains delinquent in filing its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2019, the company is not in compliance with Nasdaq Listing Rule 5250c1, which requires listed companies to timely file all required public financial reports with the Securities and Exchange Commission. The Notice has no immediate effect on the listing or trading of the company's common stock on the Nasdaq Capital Market. The Notice states that the company has until December 17, 2019 to submit to Nasdaq an updated plan to regain compliance with the Nasdaq Listing Rules. If Nasdaq accepts the company's updated plan, then Nasdaq may grant the company up to 180 days from the prescribed due date for filing the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2019, or until February 11, 2020, to regain compliance.

16:43 EST MSCI COO sells 6,000 common shares - In a regulatory filing, MSCI COO Laurent Seyer disclosed the sale of 6,000 common shares of the company at a price of $256.16 per share on November 20.

16:31 EST Blue Capital declares special distribution of 57c per common share - Blue Capital Reinsurance Holdings has declared a special distribution of 57c per common share, which is payable on December 20 to holders of record as of December 6.

16:21 EST American Equity raises annual dividend 7% to 30c per share - American Equity Investment Life Holding Company announced that its board of directors has declared an annual cash dividend of 30c per share to owners of its common stock. This is a 7% increase from the 28c per share annual dividend declared on November 15, 2018. This marks the twenty first consecutive year a cash dividend has been declared and the sixteenth year in a row that the company has increased its cash dividend. The dividend will be payable on December 12, 2019 to shareholders of record as of December 3, 2019. There are approximately 91.1M shares of common stock outstanding as of today.

16:17 EST FS Investments and KKR Credit Advisors get merger shareholder approval - FS/KKR Advisor and KKR Credit Advisors LLC, announced that the shareholders of each of four business development companies under its advisement have voted to approve all necessary proposals related to the mergers of FSIC III, FSIC IV and CCT II with and into FSIC II. The mergers will create the second largest business development company, with approximately $9 billion in assets on a pro forma basis as of September 30, 2019.

16:13 EST AMERI Holdings announces 1-for-25 reverse stock split to regain compliance - AMERI Holdings announced that it will effect a reverse split of its common stock at a ratio of 1 for 25, effective Monday, November 25. The company's common stock will begin trading on a split-adjusted basis when the markets open on the effective date under the existing trading symbol. The reverse stock split is primarily intended to bring the company into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Capital Market. The new CUSIP number for the common stock following the reverse split will be. On November 8, a majority of the company's stockholders approved giving the board discretionary authority to enact the reverse stock split. The board approved the reverse stock split on a one for twenty-five ratio on November 21. As a result of the reverse split, each 25 pre-split shares of common stock outstanding will automatically combine into one new share of common stock without any action on the part of the holders. Proportionate adjustments will be made to the conversion and exercise prices of the company's outstanding warrants and stock options. The common stock issued pursuant to the reverse stock split will remain fully paid and non-assessable. The reverse stock split will not affect the par value of the common stock which stands at 1c per share.

16:08 EST Tocagen says Phase 3 trial did not meet primary, secondary endpoints - Tocagen announced presentation of the full results from the Toca 5 Phase 3 trial evaluating Toca 511 & Toca FC in patients with recurrent high grade glioma at the Society for Neuro-Oncology Annual Meeting. The data were presented on behalf of the Toca 5 clinical investigators by Timothy Cloughesy, M.D., professor of neurology and director of the neuro-oncology program at the University of California, Los Angeles and principal investigator for the Toca 5 trial. The trial did not meet the primary or secondary endpoints. The safety, tolerability and adverse event profile of Toca 511 & Toca FC was as expected for this patient population. "The positive outcome for patients at second recurrence in the Toca 5 trial are compelling, despite the disappointment of the overall trial results," said Dr. Cloughesy. "Combined with an acceptable safety profile, these data support a potential opportunity to address the high unmet needs of this well-defined patient population and should inform any future development of the Toca 511 & Toca FC regimen."

16:01 EST Agios Pharmaceuticals presents updated data from Vorasidenib, Tibsovo study - Agios Pharmaceuticals presented updated data from the ongoing perioperative study, confirming brain penetrance and robust biomarker suppression with treatment of single agent vorasidenib or TIBSOVO in low-grade glioma with an IDH1 mutation. The data were featured in an oral presentation at the Society for Neuro-Oncology Annual Meeting in Phoenix. Vorasidenib, an investigational, oral, selective, inhibitor of the mutant isocitrate dehydrogenase-1 and IDH2 enzymes, was designed for enhanced brain penetrance and selected for pivotal development in IDH mutant low-grade glioma. "Now with data from both cohorts of the perioperative study, we have further evidence demonstrating that vorasidenib has excellent brain penetrance and suppresses 2-HG in IDH1 mutant gliomas," said Ingo Mellinghoff, M.D., Memorial Sloan Kettering Cancer Center, an investigator for the study. "In addition, it is encouraging that the safety profile continues to be consistent, and preliminary efficacy data show objective tumor responses and durable disease control with postoperative treatment. These data support the selection of vorasidenib for pivotal development and help establish the potential role for IDH inhibitors in the treatment of low-grade glioma." "These data build on our initial findings that led us to the selection of vorasidenib for a pivotal study in low-grade glioma," said Chris Bowden, M.D., chief medical officer at Agios. "Having now demonstrated brain penetrance, robust 2-HG suppression and an encouraging disease-control rate with vorasidenib, we're confident in our ability to make a difference for patients with IDH mutant low-grade glioma and are on track to initiate the Phase 3 INDIGO study next month."

15:23 EST Google's Cloud Print to no longer be supported as of December 31, 2020 - Google said that Cloud Print, its cloud-based printing solution that has been in beta since 2010, will no longer be supported as of December 31, 2020. Beginning January 1, 2021, devices across all operating systems will no longer be able to print using Google Cloud Print. The company said it recommends that over the next year, users identify an alternative solution and execute a migration strategy. Reference Link

15:00 EST Karuna CEO says no patients dropped out of Phase II study for side effects - Steve Paul is speaking on CNBC.

14:59 EST Karuna CEO says end of Phase II meeting with FDA to happen early next year - Steve Paul is speaking on CNBC.

13:52 EST David Einhorn wonders if Tesla accounts receivable exist in email to Musk - Greenlight Capital President David Einhorn took to Twitter to publicize an email he sent to Tesla CEO Elon Musk regarding the company's accounts receivable. "I'm beginning to wonder whether your accounts receivable exist," Einhorn said in the email. Tesla shares are down 6% to $334.40 in afternoon trading. Reference Link

13:01 EST Synalloy board of directors decides not to make annual dividend payment - Synalloy Corporation announces that its Board of Directors has decided not to make an annual dividend payment for 2019. The company said, "The Company's financial performance in 2019 is well below plan, with a projected operating loss for the entire year. In determining whether, or not to pay an annual dividend, the Board considered the need to maintain a strong a strong balance sheet, as well as the potential for further contraction in the manufacturing sector. The Board will review at or near the end of each fiscal year the Company's financial performance, cash and debt levels, as well as capital needed to support future growth, to determine the amount of cash dividend, if any, that may be appropriate."

12:26 EST Biogen rallies 3%, or $8.35, to $296.81

12:00 EST Pure Storage falls -18.2% - Pure Storage is down -18.2%, or -$3.62 to $16.23.

12:00 EST GSX Techedu rises 16.5% - GSX Techedu is up 16.5%, or $2.67 to $18.86.

12:00 EST Stage Stores rises 27.7% - Stage Stores is up 27.7%, or 94c to $4.33.

11:14 EST Genentech data shows Tencentriq, Avastin shows improvements in OS, PFS - Genentech, a member of the Roche Group, will present positive results from the Phase III IMbrave150 study evaluating Tecentriq in combination with Avastin. The data show statistically significant and clinically meaningful improvements in overall survival and progression-free survival, compared with sorafenib, in people with unresectable hepatocellular carcinoma who have not received prior systemic therapy. Tecentriq in combination with Avastin reduced the risk of death by 42% and reduced the risk of disease worsening or death by 41%, compared with sorafenib. Safety for Tecentriq and Avastin was consistent with the known safety profiles of the individual medicines. "For the first time in a decade, we are seeing a treatment that has improved overall survival for people with unresectable hepatocellular carcinoma compared with the current standard of care," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "Tecentriq in combination with Avastin could transform the treatment of this aggressive disease, and we are working closely with global health authorities in the hope of bringing this treatment option to patients as soon as possible." These data will be presented in the Presidential session at the European Society for Medical Oncology Asia Congress 2019.

11:01 EST Fauquier Bankshares increases quarterly dividend to 12.5c per share - Fauquier Bankshares announced that its Board of Directors on November 21, 2019 declared a quarterly dividend of 12.5c per share, an increase of a half a cent per share. This represents a 50c dividend on an annualized basis. This dividend was declared for shareholders of record as of the close of business on December 13, 2019 and will be payable on January 2, 2020.

10:35 EST Aegion's Insituform awarded $14M wastewater pipeline rehabilitation contracts - Aegion Corporation announced that its subsidiary, Insituform Technologies, LLC, has been awarded two contracts totaling over $14M from a municipal agency in New York. The combined projects require Insituform to rehabilitate more than 50 miles of 8- to 48-inch diameter wastewater pipelines using Insituform cured-in-place pipe throughout residential and commercial areas. Insituform expects to complete the installations by the end of June 2020. Since 2015, Insituform has rehabilitated more than 90 miles of 8- to 24-inch diameter wastewater pipelines for the municipality using Insituform CIPP.

10:32 EST VirnetX trading resumes

10:08 EST Cintas turns negative after Spruce Point uncovers Illinois investigation - Shares of Cintas moved lower after short-seller Spruce Point Capital claimed to have uncovered via a Freedom of Information Act request a previously undisclosed investigation into the company by the Office of the Illinois State Fire Marshal. The investigation has not been disclosed by Cintas, according to Spruce Point. The firm on November 13 issued a short report on the company, saying the shares have up to 75% downside risk. After moving higher on the open of trade, shares of Cintas are now down 43c to $253.20.

10:00 EST Pure Storage falls -19.6% - Pure Storage is down -19.6%, or -$3.88 to $15.96.

10:00 EST GSX Techedu rises 10.5% - GSX Techedu is up 10.5%, or $1.70 to $17.90.

10:00 EST The Buckle rises 15.7% - The Buckle is up 15.7%, or $3.50 to $25.80.

09:48 EST CarMax mentioned cautiously at Off Wall Street

09:47 EST Pure Storage falls -18.2% - Pure Storage is down -18.2%, or -$3.61 to $16.24.

09:47 EST The Buckle rises 11.2% - The Buckle is up 11.2%, or $2.50 to $24.80.

09:47 EST Ooma rises 15.0% - Ooma is up 15.0%, or $1.67 to $12.82.

09:30 EST Aesthetic Medical announces approx. RMB6M from VIP sale event - Aesthetic Medical International Holdings Group announced sales of approximately RMB6M from a VIP sale event on November 10, 2019, and sales of approximately RMB16M from a November 11 sale event on T-mall. On November 10, 2019, the Company invited some of VIP customers to join its listing ceremony organized in Shenzhen and organized a VIP sale event accordingly. The Company generated cash sales of approximately RMB6M contributed by approximately 150 attending customers. On November 11, 2019, the Company organized a marketing campaign on one e-commerce platform T-mall, and from that alone generated cash sales of approximately RMB16 million. During the shopping festival period from November 1 to November 11, the Company's total cash sales on various e-commerce platforms amounted to approximately RMB28M.

09:21 EST Diana Shipping announces time charter contracts for m/v Electra, m/v Protefs - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Oldendorff Carriers GmbH & Co. KG, Lubeck, Germany, for one of its Post-Panamax dry bulk vessels, the m/v Electra. The gross charter rate is $10,250 per day, minus a 5% commission paid to third parties, for a period of minimum eleven months to maximum thirteen months.The Company also announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Phaethon International Company AG, for one of its Panamax dry bulk vessels, the m/v Protefs. The gross charter rate is $9,900 per day, minus a 5% commission paid to third parties, for a period until minimum January 1, 2021 up to maximum March 31, 2021. The charter is expected to commence on November 27, 2019. The employments of "Electra" and "Protefs" are anticipated to generate approximately $7.29M of gross revenue for the minimum scheduled period of the time charters.

09:01 EST Champion Athleticwear announces collaboration with Coca-Cola - Champion Athleticwear, a brand of Hanesbrands (HBI), launched a limited-edition capsule collection, Champion X Coca-Cola, in collaboration with Coca-Cola (KO). "The brands have come together to create a unique design story expressed through bold, colorful and unexpected logo placements inspired by archived artwork. The high-energy collection, which spans men's and women's apparel as well as accessories including hats, socks, slides and bags, is currently available at Champion's six retail stores in major cities across the country and at Champs Sports and Foot Locker stores in the U.S. and Canada as well as Eastbay.com, Champion.com and Footaction stores nationwide."

09:00 EST National Storage adds Tamara Fischer to board of trustees - National Storage Affiliates Trust announced the expansion of its Board of Trustees by one additional seat and elected Tamara Fischer, the Company's current President and CFO, to the Board of Trustees, effective January 1, 2020, coincident with her appointment as CEO. As previously announced, Arlen Nordhagen, the Company's current Chairman and CEO, will be elevated to the role of Executive Chairman, and Brandon Togashi, the Company's current CAO, will be promoted to EVP and CFO, effective January 1, 2020.

08:52 EST ITC Holdings receives FERC order on MISO base ROE matter - ITC Holdings, a subsidiary of Fortis, received an order from the Federal Energy Regulatory Commission adopting a new base Return on Equity methodology for transmission owners in the Midcontinent Independent System Operator region. FERC adjusted the base ROE to 9.88% with an upper end of the zone of reasonableness at 12.24%. Including ROE incentive adders for Regional Transmission Organization participation and independence at ITC, this implies an all-in prospective ROE of 10.63% for ITC's subsidiaries operating in the MISO footprint. This compares to an all-in ROE of 11.07% that ITC was previously accruing. Every 10-basis point change in ROE at ITC impacts EPS at Fortis by approximately one cent per common share. ITC has previously recorded sufficient amounts related to the required refunds generated from the order.

08:45 EST Alexion receives approval in Japan for SOLIRIS - Alexion Pharmaceuticals announced that Japan's Ministry of Health, Labour and Welfare, or MHLW, has approved the extension of the current marketing authorization of SOLIRIS to include the prevention of relapse in patients with anti-aquaporin-4, or AQP4, antibody-positive neuromyelitis optica spectrum disorder, or NMOSD, including neuromyelitis optica.

08:38 EST Recon Technology subsidiary starts operations in Yumen City - Recon Technology announced that its 51% subsidiary, Gan Su BHD, officially started operations this month in Yumen City, Gansu Province by providing oily sludge treatment services to an oil production plant. Focusing on oily sludge treatment and disposal projects, Gan Su BHD reported daily processing capacity of 102 tons and has processed more than 2,000 tons of sludge so far. In November, Gan Su BHD provided transportation and treatment services to Laojunmiao Oil Production Plant of Yumen Oilfield Company of the China National Petroleum Corporation, including transporting 2,000 tons of oily sludge from the temporary solid waste storage site to the disposal site, and treating the oily sludge to meet the requirements of national environmental laws and regulations. Gansu Province is a landlocked province in Northwestern China with a petroleum reserve of 700M tons..

08:35 EST TOP Ships announces closing of two Financing Agreements - TOP Ships announced that it closed the previously announced two Financing Agreements with a major Chinese Financier, for total gross proceeds of $45.8M, in relation to the 50,000 dwt product/chemical tankers M/T Stenaweco Energy and M/T Stenaweco Evolution. The proceeds were used towards the reacquisition of the two vessels via the exercise of purchase options. The Company paid $47.9M for the exercise of both purchase options and the term of both facilities is 10 years.

08:35 EST Supreme Cannabis appoints John Griese as COO - Supreme Cannabis announced that John Griese has joined the company as COO. Griese brings over 30 years of executive consumer packaged goods, or CPG, and global cannabis operations experience to Supreme Cannabis. In his role as COO, Griese will be responsible for driving continuous improvements across all operating assets and leading supply chain management for Supreme Cannabis' diverse portfolio of products. Prior to joining Supreme Cannabis, Griese gained operational experience in the cannabis industry as the COO for medical and recreational cannabis companies Creso Pharma Limited and Bloom Farms in California.

08:27 EST Exagen extends collaboration agreement with GSK for lupus awareness - Exagen (XGN) announced that it has extended its collaboration agreement with GlaxoSmithKline plc (GSK) to raise awareness of the importance of timely diagnosis of systemic lupus erythematosus, the most common and severe form of lupus. At the center of the program are the proprietary AVISE laboratory tests, which can facilitate early diagnosis and management of SLE, a complex, incurable autoimmune disease. The details of the agreement are confidential. This extension follows a similar one-year extension that Exagen and GSK entered into last year, and will continue to support the shared goal of helping SLE patients shorten the time to their diagnosis, which is nearly six years on average, and to facilitate improved patient outcomes.

08:10 EST PSEG announces Ralph LaRossa as COO, Sheila Rostiac as CDO - PSEG announced several key organizational changes. Ralph LaRossa has been elected COO of PSEG. In this newly created position, LaRossa will be responsible for all operating functions of PSEG, including many of the functions within PSEG Services Corp. LaRossa also will continue in his role as president and COO of PSEG Power, the company's merchant generation business. LaRossa was elected president and COO of PSEG Power in June 2017. Previously, he served as president and COO of Public Service Electric & Gas, PSEG's regulated utility business, since October 2006. Also, Sheila Rostiac, senior VP and chief human resources officer, will take on an additional role of chief diversity officer, or CDO, merging the company's diversity and inclusion efforts within the human resources organization.

08:07 EST Office Depot CFO Joseph Lower to leave Jan. 10 to become CFO of AutoNation - Office Depot (ODP) announced that Joseph Lower, Executive Vice President and CFO, is leaving the company, effective January 10, 2020, to assume the role of CFO at AutoNation (AN). Office Depot has initiated a search for a new CFO.

08:04 EST Future Farm completes drying, curing of hemp, seeds in Maine - Future Farm Technologies announced that it has completed the drying and curing phase of its crop of hemp and seeds in Maine. Both crops achieved yields that outpace the Company's current apparatus for seed extraction, plant bucking, processing and storage. To address the success of this year's harvest, Future Farm is in the process of acquiring more robust seed extraction and cleaning equipment, additional resources for storage and transportation and larger industrial scales.

08:01 EST Zoetis acquires ZNLabs, terms not disclosed - Zoetis announced the acquisition of ZNLabs, a full-service veterinary clinical reference laboratory company with a network of labs across the U.S. This follows Zoetis' recent acquisition of Phoenix Lab as its entry into reference laboratory services and builds on a strategy to develop a more comprehensive diagnostics offering with enhanced value for veterinarians in the U.S. Financial terms of the transaction are not being disclosed.

07:51 EST Constellation plans no contributions to Canopy beyond exercise of warrants - Constellation Brands (STZ) disclosed in a regulatory filing that it recognizes equity in earnings from its equity method investment in Canopy Growth (CGC) on a two-month lag. It added, "Constellation is in a strong cash position and is projected to produce approximately $2.2 billion in operating cash flow in fiscal 2020, with equity in earnings from its equity method investment in Canopy considered non-cash. From fiscal 2020 through 2022, Constellation remains committed to returning approximately $4.5 billion in cash to shareholders in the form of share repurchases and dividends. As a reminder, the Company's original warrants with Canopy have an exercise price of C$12.98 per warrant share and will expire May 1, 2020. In addition, the Company's Tranche A warrants expire November 1, 2023. Constellation will evaluate exercise of each of these warrants immediately prior to expiration and does not plan to make additional cash contributions to Canopy beyond any possible exercise of the warrants. Constellation believes that Canopy is adequately capitalized with more than C$2.7 billion cash and marketable securities on hand as of September 30, 2019."

07:36 EST Biogen announces results from Phase 3 EVOLVE-MS-2 study - Biogen announced detailed results from the Phase 3 EVOLVE-MS-2 study demonstrating the improved patient-assessed gastrointestinal tolerability of VUMERITY, a new FDA-approved treatment for relapsing forms of multiple sclerosis, compared to TECFIDERA. These EVOLVE-MS-2 results are being presented at the 27th Annual Meeting of the European Charcot Foundation in Italy. EVOLVE-MS-2 is the first study to directly compare the GI tolerability of two relapsing MS treatments. In this study involving relapsing-remitting MS patients, VUMERITY was associated with significantly shorter duration, severity and daily impact of five key GI symptoms, compared to TECFIDERA. Results for the primary endpoint show patients treated with VUMERITY self-reported 46 percent fewer days with intensity scores of greater than or equal to2 on the Individual Gastrointestinal Symptom and Impact Scale, compared to TECFIDERA. IGISIS is a novel and exploratory scale used by patients in the study to self-assess the intensity and duration of key GI symptoms, including nausea, vomiting, upper and lower abdominal pain and diarrhea. Results observed with TECFIDERA in EVOLVE-MS-2 are consistent with its well-characterized safety profile. The EVOLVE-MS-2 results also indicate that compared to TECFIDERA, VUMERITY-treated patients had: Lower discontinuations due to GI adverse events; Fewer days with IGISIS intensity scores of greater than or equal to1 and greater than or equal to 3;Fewer days with a self-reported intensity score of greater than or equal to1, which assessed the overall intensity of GI symptoms, their impact on daily activities and how bothersome they were. Fewer days with GGISIS intensity scores of greater than or equal to2 and greater than or equal to3 were also observed. A gradual decline in worst IGISIS intensity scores over the five-week treatment period. These findings using the patient-assessed symptom intensity scales were supported by lower investigator-reported incidences of GI AEs with VUMERITY compared to TECFIDERA. Overall AEs occurred in 78.3 percent of patients with VUMERITY and 83.7 percent with TECFIDERA. Most AEs were mild or moderate in severity. The overall proportion of patients with AEs leading to study discontinuation were 1.6 percent for VUMERITY and 5.6 percent for TECFIDERA. EVOLVE-MS-2 was a multi-center, double-blind, active-controlled, five-week Phase 3 study designed to evaluate the GI tolerability, including duration and severity, of VUMERITY compared to TECFIDERA in 506 patients with RRMS. The study's primary endpoint assessed the number of days patients reported GI symptoms with a symptom intensity score greater than or equal to2 on the IGISIS rating scale. Secondary endpoints evaluated the number of days that patients reported GI symptoms with an IGISIS intensity scores of greater than or equal to1 or greater than or equal to3 in the overall population; IGISIS intensity score of greater than or equal to2 in patients from Part B only; GGISIS intensity scores of greater than or equal to1, greater than or equal to2, or greater than or equal to3 in the overall population; and worst IGISIS individual symptom score by study week. Patients who completed the five-week treatment period were eligible to enroll in EVOLVE-MS-1, a 96-week, open-label, safety study for VUMERITY.

07:30 EST Anixter, CD&R announce amendment to up merger consideration to $82.50 per share - As previously announced, on October 30, Anixter entered into an agreement and plan of merger to be acquired by a fund sponsored by Clayton, Dubilier & Rice, or CD&R, in an all cash transaction valued at approximately $3.8B. Anixter announced that Anixter and CD&R agreed to an amendment to the merger agreement to increase the per-share consideration payable to Anixter's shareholders to $82.50 per share in cash from $81.00 per share in cash. The revised per-share consideration represents a premium of approximately 15.5% over Anixter's closing price on October 29 and a premium of approximately 30% over the 90-day volume-weighted average price of Anixter's common stock for the period ended October 29. The transaction is now valued at approximately $3.9B. Under the terms of the amended merger agreement, Anixter may solicit superior proposals from third parties through November 24. Anixter advises that there can be no assurance that the solicitation process will result in an alternative transaction. To the extent that the merger agreement is terminated for a superior proposal prior to November 24 or, in certain circumstances, five days thereafter, Anixter would be obligated to pay a $60M break-up fee to CD&R. If the merger agreement is terminated for a superior proposal after the aforementioned period, Anixter would be obligated to pay a $100M break-up fee to CD&R. Anixter does not intend to disclose developments with respect to this solicitation process unless and until it determines it is appropriate to do so. The transaction is subject to the approval of Anixter's stockholders, regulatory approvals and other customary closing conditions.

07:18 EST Astrotech says 1st Detect sells TRACER 1000s to shipping & logistics company - Astrotech Corporation announced that 1st Detect has signed a contract with a global shipping and logistics company and is already fulfilling purchase orders. Under the terms of the contract, the 1st Detect TRACER 1000 has been approved on the company's approved vendor list and is now available for corporate-wide purchases on pre-negotiated terms.

07:16 EST Destination XL to close two Rochester Clothing stores, one DXL store in Q4

07:13 EST Anixa Biosciences announces Cchek study collaboration with UCA - Anixa Biosciences announced a collaboration with Urology Centers of Alabama, or UCA, in the Cchek early prostate cancer detection study. UCA will provide patient samples in Anixa's ongoing study, including support of clinical validation of Anixa's Cchek Prostate Cancer Confirmation test. UCA is one of several sites across the U.S. participating in this study.

07:09 EST Energizer targets 'top-line growth above category' in FY20-FY22 - Also targets adjusted cumulative gross margin expansion of 250bps, adjusted EBITDA growth per year in the mid-teens, and over $100M in synergy cost savings from network optimization. Outlook from the company's Analyst Day presentation released yesterday afternoon.

07:08 EST J.M. Smucker CEO says Q2 sales performance did not meet expectations - "While our second quarter sales performance did not meet our expectations, we delivered EPS growth ahead of our projection, reflecting our commitment to maintain financial discipline and strengthen our bottom line," said Mark Smucker, president and CEO. "Despite continuing softness for our premium dog food offerings, we were pleased with the performance for the balance of our portfolio, as the momentum for our cat food and pet snacks businesses continued with year over year sales increases, our high growth coffee brands improved household penetration and market share, and Smucker's(R) Uncrustables(R) grew 19 percent, helping accelerate growth in snacking. Looking ahead, the actions we are taking across the Company, including the recently announced leadership changes, position us well for future long-term growth and shareholder value creation."

07:04 EST Destination XL appoints Ujjwal Dhoot as CDO - Destination XL Group announced that Ujjwal Dhoot has joined its team as chief digital officer. Prior to joining DXL, Dhoot held senior marketing positions with FSAstore.com, Charming Charlie and PetCareRx.com. At DXL, he will be responsible for all digital initiatives across the entire organization, including building the brand digitally, driving traffic to stores, mobile commerce, ecommerce, and the Company's overarching digital marketing strategy. Dhoot will effectively join the Company on December 16, 2019 and in connection with his employment, he will receive a $125,000 sign-on award of restricted stock units. The number of shares will be determined on that day based on the Company's previous trading day's closing stock price. The RSUs will vest on April 1, 2020 and will be subject to claw-back if Mr. Dhoot terminates his employment voluntarily and without good reason before January 30, 2022.The RSUs will be granted outside of the Company's stockholder-approved stock compensation plan. The RSUs were approved by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to Dhoot's entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

07:02 EST Wingstop appoints Christina Clarke as CMO - Wingstop announced the appointment of Christina Clarke as chief marketing officer, previously interim CMO of Wingstop, and Donnie Upshaw as SVP of people, previously VP of Human Resources. .

06:58 EST Aecom board to initiate CEO succession process

06:58 EST Aecom says Steven A. Kandarian to serve as board's lead independent director

06:57 EST Aecom says Chairman and CEO Michael Burke intends to retire

06:54 EST Hibbett Sports announces strategic realignment, accelerated store closure plan - Hibbett Sports announced the following: "As the retail environment continues to evolve, the company is focused on improving the productivity of the store base while continuing to grow its omni-channel business to serve customers where and when they want to shop. As previously reported, the company is proceeding with the closing of approximately 95 Hibbett stores in FY20, which is expected to result in non-recurring impairment and store closure charges in the range of 8c-12c per diluted share in FY20."

06:50 EST Mednax announces affiliation with Associated Pediatricians of Homestead - Mednax announced its affiliation with Arcenio Chacon and Associated Pediatricians of Homestead, a private pediatric critical care and hospitalist practice based in Miami. Founded in 1993, the practice is a group that has served Baptist Health South Florida for more than 25 years. Comprising four physicians, the group provides pediatric critical care and hospitalist services at Baptist Children's Hospital and hospitalist services at Miami Cancer Institute and Homestead Hospital.This affiliation adds to the services Mednax provides in Florida through its network of affiliated physicians across multiple specialties, including maternal-fetal medicine, OB hospitalist, neonatology, newborn hearing screen, pediatric cardiology, pediatric critical care, pediatric hospitalist, pediatric surgery/plastic surgery, pediatric urology, developmental pediatrics, anesthesiology and radiology. This was a cash transaction, and it is expected to be immediately accretive to earnings. No additional terms of the transaction were disclosed.

06:47 EST Foot Locker reports Q3 gross margin 32.1% vs. 31.6% last year

06:21 EST ReneSola, BNY Mellon reach agreement to waive annual depository service fee - ReneSola (SOL) announced that the company and Bank of New York Mellon (BK), the company's depositary bank for its American depositary shares , or ADSs, have reached an agreement to waive the annual depositary service fee for the holders of the company's ADSs. BNYM currently charges the holders of ReneSola's ADSs a fee of 2c per ADS per annum for depositary services. The agreement specifies that, effective November 21, ReneSola will make an annual payment to BNYM for depositary services on behalf of its shareholders.

05:19 EST Autohome appoints Xiao Wang as Chief Technology Officer - Autohome announced the appointment of Xiao Wang as the Chief Technology Officer of the company. The appointment took effect on November 22. Xiao Wang has served as the company's vice president of big data since August 2017.